Skip to Main Content

Try STAT+ TODAY

drug pricing

Most Read

Politics Rachel Cohrs

In a momentous vote for Pelosi, House sends drug pricing reforms to President Biden’s desk

Pharmalot Ed Silverman

Wyden wants details on Amgen’s U.S. taxes as part of expanding probe into pharma practices

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Big egos in Big Science, the return of Merger Monday, & the fallout over drug pricing

Politics Rachel Cohrs

Here’s who Democrats’ drug pricing bill will actually help

Pharmalot Ed Silverman

For the second time, Pfizer tries a warranty in response to concerns over high drug costs

Politics Rachel Cohrs

In a massive victory for Democrats, Medicare is poised to negotiate drug prices

Politics Rachel Cohrs

Democrats dramatically narrow their ambitions for lowering insulin costs

Politics Rachel Cohrs

Democrats will have to limit their drug pricing reforms to Medicare to comply with Senate rules

All Coverage

Pharmalot Ed Silverman

Cepheid faces fresh criticism over the pricing of its TB diagnostics

Politics Rachel Cohrs

Unpacking the drug pricing policies that Congress just approved

advertisement

Pharmalot Ed Silverman

Sales from controversial drug discount program rose to $44 billion last year

Politics Rachel Cohrs

Cancer patient who devoted six years to drug pricing reform isn’t done yet

Matt's Take Matthew Herper

The Senate’s drug pricing bill is an inevitable solution. It will still have plenty of unintended consequences

Politics Rachel Cohrs

The glaring health equity gap in Democrats’ drug pricing plan

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: The last-minute push for drug pricing reform, Alnylam’s success, and Sarepta’s gamble

First Opinion Standish Fleming

The outsized effect of ‘modest’ price controls on pharmaceutical innovation

Pharmalot Ed Silverman

Lilly is ordered to pay $61 million for shortchanging the Medicaid drug rebate program

Pharmalot Ed Silverman

Civica Rx begins selling its first outpatient generic drug as it tries to overhaul the pharmaceutical supply chain

First Opinion Kenneth E. Thorpe

WTO: Don’t make a bad situation worse by granting intellectual property waivers for Covid-19 therapeutics and diagnostics

D.C. Diagnosis Rachel Cohrs

The view on drug pricing from Wall Street, a pharma-friendly Dem holds firm, and what’s next for a big telehealth bill

Pharmalot Ed Silverman

AbbVie is scolded by a trade group over sales rep ‘strategically loitering’ in a hospital

Pharmalot Ed Silverman

Wyden says Merck and Abbott aren’t cooperating with probe into pharma tax practices

Politics Rachel Cohrs

‘What can we do?’: Pharma lobbyists face their biggest test in a decade, as Democrats barrel toward a vote on drug pricing

Pharmalot Ed Silverman

Pfizer loses another court battle alleging the U.S. illegally limits use of copay assistance programs

First Opinion Craig Garthwaite

Drug price controls are a dance with the devil: short-term savings will be overwhelmed by loss of innovation

Politics Nicholas Florko

Powerful Senate Democrat outlines ‘plenty’ more drug pricing reforms to follow Medicare negotiation

Health Care Rachel Cohrs

Virtual Event: Democrats’ Last Chance for Drug Pricing Reform?

D.C. Diagnosis Nicholas Florko

PhRMA and BIO descend on D.C. & unpacking the Senate’s FDA funding drama

Politics Nicholas Florko

The politics of passing a major FDA funding bill just got complicated

Pharmalot Ed Silverman

Dozens of lawmakers urge HHS to fine drugmakers for curtailing discounts to a federal program

Pharmalot Ed Silverman

Federal patent initiatives could cause ‘headwinds’ for drugmakers and their broad filings

Politics Alan Fram — Associated Press

Biden tells Dems to quickly pass pared-down economic package

First Opinion Girisha Fernando

Value-based drug pricing: When does it work best?